Toremifene reduces fracture risk in men with prostate cancer after initiation of androgen deprivation therapy

GTx, Inc. (NASDAQ: GTXI) today announced that additional study results from the Phase III clinical trial evaluating toremifene 80 mg for the prevention of fractures in men with prostate cancer on androgen deprivation therapy will be presented at the 2010 Annual Meeting of the American Urological Association being held in San Francisco May 29-June 3.

“Multivariate analysis demonstrates treatment with toremifene 80 mg reduces fracture risk after initiation of androgen deprivation therapy”

Podium presentation: "Toremifene improves PSA progression free survival in castrate men with detectable baseline PSA levels"

• Sunday, May 30, 2010, 3:30 - 5:30 p.m.
• Moscone South, Room 104

Moderated poster presentation: "Multivariate analysis demonstrates treatment with toremifene 80 mg reduces fracture risk after initiation of androgen deprivation therapy"

• Monday, May 31, 2010, 10:30 a.m. - 12:30 p.m.
• Moscone North, Room 130-131